Investigational drug · Phase 2
BEAM-201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BEAM-201"
First trial start
2023
May 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BEAM-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoblastic Lymphoma
- T-Cell Lymphoblastic Leukemia/Lymphoma
- Lymphoblastic Leukemia
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BEAM-201" as an intervention, largest first.
- Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or LymphomaActive, not recruiting
Stephan Grupp MD PhDAcademic, hospital or other
NCT06934382 · 33 participants (planned) · Start Apr 29, 2025 · Primary completion May 30, 2029
Drug: Allogeneic anti-CD7 CAR-T cells (BEAM-201) · For: T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Sites: Philadelphia, Pennsylvania
- A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)Active, not recruiting
Beam Therapeutics Inc.Industry
NCT05885464 · 5 participants · Start May 25, 2023 · Primary completion Dec 2026
Drug: BEAM-201 · For: Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia
Sites: Stanford, California; Denver, Colorado; Chicago, Illinois · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.